Clinical Trials Browser

Breast Neoplasms, Triple Negative Breast Neoplasms

Advanced Breast Cancer

Carcinoma, Hepatocellular, Liver Neoplasms

Nasopharyngeal Carcinoma

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

Locally Advanced Rectal Cancer

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Advanced Malignant Solid Tumors

Esophageal Squamous Cell Carcinoma

Muscle Invasive Bladder Cancer (MIBC)

Pancreatic Neoplasms

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Papillomavirus Infections

Triple Negative Breast Neoplasms

Carcinoma, Renal Cell

Head and Neck Neoplasms

Small Cell Lung Carcinoma

Local Advanced Non-small Cell Lung Cancer

Carcinoma, Hepatocellular

Breast Neoplasms

Ovarian Neoplasms

Nasopharyngeal Carcinoma

Oropharyngeal Neoplasms

Small Cell Lung Cancer Limited Stage

Breast Neoplasms

Small Cell Lung Carcinoma

Uterine Cervical Neoplasms, Neoplasm Metastasis, Recurrence

Clinical Trials

FACT-TN

Toripalimab as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors

2025-370

A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

LIGHT

WOLF

TORCH-iTNT

Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC

Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer

The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer

(NeoScorch HN)

NEOTRIO-2

PLUTO

A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

InTRist

A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients

Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy

IPROC

Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer

Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy

Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer